Search the Newsreel

Krystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysis

Krystal Biotech Inc (KRYS) currently has a valuation score of 7.39, placing it 177th out of 385 in the Biotechnology & Medical Research industry. Its P/E ratio stands at 44.04, significantly differing from its recent high and low. Data for P/B, P/S, and P/CF …

Krystal Biotech slides as investors appear to reset ahead of earnings

Krystal Biotech (KRYS) saw an 8.7% decline in its stock price, potentially due to traders taking profits and reducing risk ahead of its Q2 2026 earnings report on August 3. The company previously reported strong Q1 2026 results with $116.4 million in revenue and …

Krystal Biotech earnings in focus as Vyjuvek expansion accelerates By Investing.com

Krystal Biotech Inc. is set to announce its second-quarter results, with analysts anticipating EPS of $1.75 on revenue of $122.61 million, indicating strong year-over-year growth for its flagship product Vyjuvek. Investors will closely monitor the company's ability to sustain U.S. growth and accelerate international …

Krystal Biotech Drops 5.9% Amid Sector-Wide Selling

Krystal Biotech (KRYS) shares fell 5.9% to $345.35 on Friday, July 31, 2026, as part of a broader sector-wide selloff impacting biotechnology stocks. This decline, mirroring losses in other biotech firms like Madrigal Pharmaceuticals and Cytokinetics, suggests broad-based selling pressure rather than company-specific concerns. …

How Krystal Biotech Inc. (KRYS) Affects Rotational Strategy Timing

This article analyzes Krystal Biotech Inc. (KRYS) and its impact on rotational strategy timing, identifying a mid-channel oscillation pattern. It highlights strong near-term sentiment while suggesting neutrality mid-term and a positive long-term bias. The analysis provides specific institutional trading strategies for long, breakout, and …

Krystal Biotech (KRYS) Is Up 7.9% After S&P 400 Move And New KB801 Patent Filing Update

Krystal Biotech (KRYS) stock rose 7.9% following its inclusion in the S&P 400 index and an update on its KB801 gene therapy patent filing. The patent filing included single-patient data from a discontinued study for neurotrophic keratitis, with the company emphasizing the data's early …

Krystal Biotech (KRYS) After The KB801 Update And Why Valuation Still Splits Opinion

Krystal Biotech (KRYS) recently shared new single-patient data regarding its KB801 gene therapy for neurotrophic keratitis, despite the study being discontinued. The company's stock has shown strong momentum, but valuation opinions are split, with some analysts considering it slightly overvalued at $361.67, while a …

Krystal Biotech Inc (KRYS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Krystal Biotech Inc (KRYS), detailing its current price momentum, support and resistance levels, and various technical indicator signals. The stock's price momentum score is 3.84, with trading between 331.98 support and 389.51 resistance. Moving averages overwhelmingly show …

Krystal Biotech, Inc. (KRYS) Stock Analysis: Biotechnology Pioneer with 12.40% Potential Upside

Krystal Biotech, Inc. (KRYS) is a commercial-stage biotechnology company with a market capitalization of $9.88 billion, known for its genetic medicines like VYJUVEK for dystrophic epidermolysis bullosa. The company shows strong financial performance with a 31.90% revenue growth rate, 19.90% ROE, and a positive …

AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Krystal Biotech, Inc. Revenue Breakdown – NASDAQ:KRYS

Krystal Biotech, Inc. (NASDAQ: KRYS) generated $389.13 million USD in revenue last year, primarily from its Genetic Medicines segment. The company's revenue increased from $290.51 million USD in the previous year, with the United States being the greatest contributor to its sales.

KRYS|Krystal Biotech Inc|Price:335.190|Chg%:+7.690

Krystal Biotech Inc. (KRYS) shows strong fundamentals, high growth potential, and is considered fairly valued in the Biotechnology & Medical Research industry, ranking 7 out of 386. The company's revenue has grown consistently, and its latest net income leads the industry. Analysts currently rate …

Krystal Biotech, Inc. (KRYS) Stock Price, News, Quote & History

This article provides a comprehensive overview of Krystal Biotech, Inc. (KRYS), including its current stock price, financial statistics, and company profile. It details the company's focus on genetic medicines, its commercialized product VYJUVEK, and its pipeline of drug candidates for various conditions. The report …

Krystal Biotech, Inc.(NasdaqGS:KRYS) added to S&P 400 - Biotechnology

Krystal Biotech, Inc. (NasdaqGS:KRYS) has been added to the S&P 400 index, specifically within the Biotechnology sector. This move comes as part of broader index changes, with Krystal Biotech replacing Taylor Morrison Home in the S&P MidCap 400. The company, which is a commercial-stage …

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

Krystal Biotech, Inc. (NASDAQ: KRYS) announced it will report its second quarter 2026 financial results on Monday, August 3, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 am ET on the same day to discuss the results …

Krystal Biotech sets Aug. 3 webcast before U.S. markets open

Krystal Biotech (NASDAQ: KRYS) announced it will report its second-quarter 2026 financial results on Monday, August 3, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 a.m. ET on the same day for investors and the public. A …

Is A Single-Patient KB801 Outcome Quietly Reframing Krystal Biotech's Clinical Narrative (KRYS)?

Krystal Biotech (KRYS) recently disclosed a single-patient outcome from a discontinued KB801 gene therapy study in a patent filing, where one patient with neurotrophic keratitis experienced full corneal defect closure without serious side effects. While the company stated this disclosure does not imply overall …

Is Krystal Biotech (KRYS) Overvalued On Its KB801 Patent Data Update?

Krystal Biotech (KRYS) recently updated its KB801 patent data with previously undisclosed single patient information, though emphasizing it's not a substitute for clinical trials. Despite a slight share price dip, Krystal Biotech exhibits strong momentum, yet a popular narrative suggests it's 40.7% overvalued at …

Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing

Krystal Biotech has filed a response with the United States Patent and Trademark Office (USPTO) regarding its KB801 patent application. This information originates from an SEC filing. The article highlights this development, suggesting it's a significant event for the biotechnology company.

Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Report - Results, Call & Slides

Krystal Biotech (KRYS) reported its Q1 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of $0.03 against a consensus of $0.27 and actual revenue of $45.25 million against an expected $47.37 million. The report also includes details on …

Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

This article announces that Krystal Biotech will join the S&P MidCap 400 index, and Tutor Perini and V2X will be added to the S&P SmallCap 600 index. These changes are effective prior to the open of trading on July 29, 2026. The new additions …

Krystal Biotech Set to Enter S&P MidCap 400 as Two Join

S&P Dow Jones Indices announced changes to the S&P MidCap 400 and S&P SmallCap 600, effective July 24 and July 27, 2026. Krystal Biotech (KRYS) will move from the S&P SmallCap 600 to the S&P MidCap 400, replacing Taylor Morrison Home (TMHC), which is …

(KRYS) and the Role of Price-Sensitive Allocations

This article analyzes Krystal Biotech Inc. (NASDAQ: KRYS), noting a weak near and mid-term sentiment despite a positive long-term outlook. It highlights a significant 34.8:1 risk-reward setup targeting a 10.0% gain with only 0.3% risk. The analysis includes three institutional trading strategies (Position, Momentum …

KRYS Jumps As Wall Street Hikes Price Targets On Vyjuvek Momentum

Krystal Biotech Inc. (KRYS) stock jumped by 5.91% after Wall Street analysts, including BofA and Jefferies, raised their price targets due to strong Vyjuvek momentum and confidence in its pipeline. The company's financial health is robust with high margins, positive earnings, and a strong …

KRYS Jumps As Analysts Race To Lift Price Targets

Krystal Biotech Inc. (KRYS) stock is trading up by 5.91% following strong analyst coverage and raised price targets from BofA, Jefferies, and TD Cowen. Analysts cite sustained demand for Vyjuvek, growing international revenue, and promising pipeline assets as key drivers. The company's strong financial …

KRYS Jumps As Wall Street Lifts Bullish Price Targets

Krystal Biotech Inc. (KRYS) stock jumped by 5.91% following several analysts, including BofA, Jefferies, and TD Cowen, raising their price targets due to strong performance of its gene therapy Vyjuvek, promising pipeline developments, and robust financial fundamentals. The company is highlighted as a profitable, …

Krystal Biotech Rises as Investors Lean on Commercial Momentum and Pipeline Catalysts

Krystal Biotech (KRYS) saw a 5.9% stock increase, driven by strong commercial performance of VYJUVEK and promising late-stage pipeline catalysts, including upcoming 2026 data readouts for KB803 and KB801. The company reported $116.4 million in Q1 2026 global revenue for VYJUVEK, a 32% year-over-year …

Is Krystal Biotech (KRYS) Too Expensive After A 440% Return?

Krystal Biotech (KRYS) has seen an impressive 440% return over five years and 129.8% in the last year, but a recent analysis suggests its current valuation is expensive. The company's P/E ratio of 44.5x is significantly higher than the biotech industry average of 17.2x …

Krystal Integrated Services Wins ₹27.64 Cr Sanitation Order from Andhra Pradesh Govt

Krystal Biotech (KRYS) Revenue Growth Puts VYJUVEK Pipeline Progress In Focus

There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings

Small-cap stock Krystal Integrated Services jumps 2.5% despite stock market sell-off

Krystal Integrated Services Reports Q3FY26 Results, Approves ₹300 Crore QIP and Capital Increase

Is Krystal Integrated Services (NSE:KRYSTAL) Using Too Much Debt?